Pathology services-provider AmeriPath's high bad debt expense is partly a result of its position as a secondary recipient of billing information, a factor in Moody's Investors Service's rating of the company's $365 million credit at B1. Unlike other laboratory companies, much of AmeriPath's revenue stems from an inpatient hospital setting, causing it to depend on the hospitals for billing data. Several other labs are able to send their bills directly to patients, which helps expedite and ensure payment at a reliable rate, explained Russell Pomerantz, v.p. and senior analyst at Moody's. The bank facility backs plans by Welsh, Carson, Anderson & Stowe to acquire the cancer diagnostics provider for about $845 million.
March 16, 2003